• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[抗胃癌单克隆抗体及其在不同组织上的选择性反应]

[Monoclonal antibodies against gastric cancer and their selective reaction on various tissues].

作者信息

Wei S M

机构信息

Beijing Institute for Cancer Research.

出版信息

Zhonghua Zhong Liu Za Zhi. 1989 May;11(3):162-4.

PMID:2558869
Abstract

Spleen cells from Balb/c mice immunized in sequence with five human gastric cancer cell lines were fused with murine myeloma cell line SP2/0. Hybridomas 3F4, 3G9 and 3H11 secreting monoclonal antibodies (mAb) against gastric cancer were obtained through selective culture and screening. These mAb produced by the immunization procedure have good selectivity and high positive rate in reaction on gastric cancer. The positive rate of reaction on gastric cancer cells and tissues could reach 5/5 and 84.8-93.5%, respectively, whereas there was almost no positive reaction on normal cells and tissues As there was no correlation between the positive reaction of gastric cancer and their histopathologic typing, and the cross reaction of mAb with other tumors and fetal gastrointestinal tissues was quite high, the corresponding antigens of these mAb were considered as extensive oncofetal antigens.

摘要

将依次用五种人胃癌细胞系免疫的Balb/c小鼠的脾细胞与鼠骨髓瘤细胞系SP2/0进行融合。通过选择性培养和筛选,获得了分泌抗胃癌单克隆抗体(mAb)的杂交瘤3F4、3G9和3H11。通过免疫程序产生的这些单克隆抗体在对胃癌的反应中具有良好的选择性和高阳性率。对胃癌细胞和组织的反应阳性率分别可达5/5和84.8 - 93.5%,而对正常细胞和组织几乎没有阳性反应。由于胃癌的阳性反应与其组织病理学类型之间没有相关性,且单克隆抗体与其他肿瘤和胎儿胃肠道组织的交叉反应相当高,因此这些单克隆抗体的相应抗原被认为是广泛的癌胚抗原。

相似文献

1
[Monoclonal antibodies against gastric cancer and their selective reaction on various tissues].[抗胃癌单克隆抗体及其在不同组织上的选择性反应]
Zhonghua Zhong Liu Za Zhi. 1989 May;11(3):162-4.
2
[In vivo localization of labeled monoclonal antibody 3G9 against human gastric cancer in tumor-bearing nude mice].[荷瘤裸鼠体内抗人胃癌标记单克隆抗体3G9的定位]
Zhonghua Zhong Liu Za Zhi. 1989 Mar;11(2):85-8.
3
[Monoclonal antibody A12 against gastric cancer produced in immuno-reconstituted nude mice].免疫重建裸鼠制备的抗胃癌单克隆抗体A12
Zhonghua Zhong Liu Za Zhi. 1992 Jul;14(4):257-60.
4
[Immunoelectron microscopic study on the localization of monoclonal antibodies on gastric cancer cells].[单克隆抗体在胃癌细胞上定位的免疫电子显微镜研究]
Zhonghua Zhong Liu Za Zhi. 1991 Mar;13(2):87-9.
5
[Preparation and identification of monoclonal antibody against the gastric cancer cell line MGC 803].[抗胃癌细胞系MGC 803单克隆抗体的制备与鉴定]
Zhonghua Zhong Liu Za Zhi. 1986 Jan;8(1):8-10.
6
[Study of anticancer human monoclonal antibody--establishment of human monoclonal antibody to gastric cancer by human-mouse hybridoma].抗癌人单克隆抗体的研究——用人-鼠杂交瘤技术制备抗胃癌人单克隆抗体
Zhonghua Zhong Liu Za Zhi. 1988 Jul;10(4):242-4.
7
Human monoclonal antibody reactive to stomach cancer produced by mouse-human hybridoma technique.用人鼠杂交瘤技术制备的抗胃癌人单克隆抗体。
Jpn J Cancer Res. 1986 Nov;77(11):1122-33.
8
[Distribution of monoclonal antibodies MG7 and MGd-1 against gastric carcinoma in stomach cancer].抗胃癌单克隆抗体MG7和MGd-1在胃癌中的分布
Zhonghua Zhong Liu Za Zhi. 1990 May;12(3):193-5.
9
Production of anti-tumor human monoclonal antibodies using different approaches.使用不同方法生产抗肿瘤人单克隆抗体。
Hum Antibodies Hybridomas. 1993 Jan;4(1):2-8.
10
[The selective cytotoxicity of monoclonal antibody conjugated with mitomycin C on human gastric cancer cells].丝裂霉素C偶联单克隆抗体对人胃癌细胞的选择性细胞毒性
Yao Xue Xue Bao. 1989;24(11):801-6.

引用本文的文献

1
Monoclonal antibody 3H11 chimeric antigen receptors enhance T cell effector function and exhibit efficacy against gastric cancer.单克隆抗体3H11嵌合抗原受体增强T细胞效应功能并对胃癌显示出疗效。
Oncol Lett. 2018 May;15(5):6887-6894. doi: 10.3892/ol.2018.8255. Epub 2018 Mar 13.
2
SLC3A2, antigen of mAb 3G9, promotes migration and invasion by upregulating of mucins in gastric cancer.SLC3A2,单克隆抗体3G9的抗原,通过上调胃癌中的黏蛋白促进迁移和侵袭。
Oncotarget. 2017 Jul 25;8(51):88586-88598. doi: 10.18632/oncotarget.19529. eCollection 2017 Oct 24.